SSC-SYSTEMIC SCLEROSIS
Clinical trials for SSC-SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new SSC-SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for SSC-SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a second drug help scleroderma patients breathe easier?
Disease control Recruiting nowThis study looks at whether adding an anti-fibrotic drug to standard double immunosuppression can better preserve lung function in people with scleroderma-related interstitial lung disease (ILD). About 35 adults will be followed for 12 months with regular breathing tests. The goa…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Sponsor: University of Patras • Aim: Disease control
Last updated May 26, 2026 07:08 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that cause autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment is given as a one-time infusion and aims…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 06:58 UTC
-
Engineered immune cells take aim at Hard-to-Treat scleroderma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1195E CAR-T cells for people with severe systemic sclerosis (scleroderma) that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack the disease. The ma…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New drug CC312 tested in severe autoimmune patients
Disease control Recruiting nowThis early-stage study tests the safety of a new drug, CC312, in 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check for side effects, not to cure the disease. Participants receive multiple doses of the drug and a…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 19, 2026 11:47 UTC